The component of the m 6 A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors

• Published in: Journal of experimental & clinical cancer research Vol. 40; no. 1; p. 268
• Main Authors: Miranda-Gonçalves, Vera, Lobo, João, Guimarães-Teixeira, Catarina, Barros-Silva, Daniela, Guimarães, Rita, Cantante, Mariana, Braga, Isaac, Maurício, Joaquina, Oing, Christoph, Honecker, Friedemann, Nettersheim, Daniel, Looijenga, Leendert H J, Henrique, Rui, Jerónimo, Carmen
• Format: Journal Article
• Language: English
• Published: England 25-08-2021
• Subjects: Adenosine - analogs & derivatives; Adenosine - physiology; Antineoplastic Agents - therapeutic use; Cell Line, Tumor; Cisplatin - therapeutic use; DNA Damage; Drug Resistance, Neoplasm - physiology; Gene Knockdown Techniques; Humans; Male; Methyltransferases - physiology; Neoplasms, Germ Cell and Embryonal - drug therapy; Neoplasms, Germ Cell and Embryonal - genetics; Neoplasms, Germ Cell and Embryonal - pathology; RNA-Binding Proteins - genetics; RNA-Binding Proteins - physiology; Epitranscriptomics; CRISPR/Cas9; Germ cell tumors; N6-methyladenosine; DNA repair; VIRMA; CAM; Cisplatin; RNA modifications
• ISSN: 1756-9966

Germ cell tumors (GCTs) are developmental cancers, tightly linked to embryogenesis and germ cell development. The recent and expanding field of RNA modifications is being increasingly implicated in such molecular events, as well as in tumor progression and resistance to therapy, but still rarely explored in GCTs. In this work, and as a follow-up of our recent study on this topic in TGCT tissue samples, we aim to investigate the role of N6-methyladenosine (m
A), the most abundant of such modifications in mRNA, in in vitro and in vivo models representative of such tumors.
Four cell lines representative of GCTs (three testicular and one mediastinal), including an isogenic cisplatin resistant subline, were used. CRISPR/Cas9-mediated knockdown of VIRMA was established and the chorioallantoic membrane assay was used to study its phenotypic effect in vivo.
We demonstrated the differential expression of the various m
A writers, readers and erasers in GCT cell lines representative of the major classes of these tumors, seminomas and non-seminomas, and we evidenced changes occurring upon differentiation with all-trans retinoic acid treatment. We showed differential expression also among cells sensitive and resistant to cisplatin treatment, implicating these players in acquisition of cisplatin resistant phenotype. Knockdown of VIRMA led to disruption of the remaining methyltransferase complex and decrease in m
A abundance, as well as overall reduced tumor aggressiveness (with decreased cell viability, tumor cell proliferation, migration, and invasion) and increased sensitivity to cisplatin treatment, both in vitro and confirmed in vivo. Enhanced response to cisplatin after VIRMA knockdown was related to significant increase in DNA damage (with higher γH2AX and GADD45B levels) and downregulation of XLF and MRE11.
VIRMA has an oncogenic role in GCTs confirming our previous tissue-based study and is further involved in response to cisplatin by interfering with DNA repair. These data contribute to our better understanding of the emergence of cisplatin resistance in GCTs and support recent attempts to therapeutically target elements of the m
A writer complex.